The present study aimed to investigate the anti-tumor effects of an oncolytic adenovirus, H101, in combination with a PD-1 inhibitor, Camrelizumab, in a humanized immune system mouse model of cancer. The gene discussed is PDCD1; the disease is neoplasm.